Hence, they evaluated: (i) the levels of AFB1-lysine adduct in plasma samples of patients with gallstones, gallbladder cancer and gallstones without cancer; and (ii) the R249S mutation in TP53 that is associated with AFB1 exposure in tumour tissues from gallbladder cancer patients. The gene discussed is TP53; the disease is gallbladder cancer.